莱纳利多米德和德克萨米松治疗罗莎-多夫曼病:单臂,单中心,前性第二阶段研究
Long Chang1,2, Min Lang1,2, Ting Liu1,3
1Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China.
EClinicalMedicine
|July 18, 2024
概括
列纳利多米德和甲对罗莎-多夫曼病 (RDD) 的治疗有希望. 这种治疗在第二阶段的研究中实现了87%的总体反应率,并具有可控的副作用,为RDD患者提供了新的选择.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 罗莎-多夫曼病 (RDD) 是一种罕见的囊细胞性疾病,没有确定的一线治疗方法.
- 这项研究解决了对有效RDD疗法的需求.
研究的目的:
- 评估莱纳利多米德加德克萨米他 (RD) 对新诊断和复发的罗莎-多夫曼病的疗效和安全性.
- 评估无进展生存率 (PFS),整体反应率 (ORR) 和整体生存率 (OS).
主要方法:
- 一个单一中心的第二阶段前性研究,涉及23名RDD患者 (13名新诊断,10名复发).
- 患者接受了lenalidomide (25 mg 1-21天) 和dexamethasone (40 mg 1,8,15,22天) 在28天的周期,长达12个周期.
- 主要终点是PFS;次要终点包括ORR,毒性和OS.
主要成果:
- 观察到的整体响应率 (ORR) 为87% (30%完全缓解,57%部分缓解).
- 治疗显著降低了升高的IL-6和TNF-α血清水平.
- 随访时间中位数为26个月;两年的OS和PFS分别为100%和69%.
- 没有发生3-4级不良事件;大多数毒性是1-2级血液问题.
结论:
- 列纳利多米德和甲治疗方案是新诊断的和复发的罗莎-多夫曼病的有效和安全的治疗选择.
- 这种组合疗法在RDD患者中显示出显著的临床益处和耐受性.
相关概念视频
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
01:01Dosage Regimen: Fixed Dose
2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
383
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
383